ProfileGDS5678 / 1455171_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 66% 67% 65% 69% 67% 66% 62% 68% 67% 68% 68% 67% 67% 67% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.0465466
GSM967853U87-EV human glioblastoma xenograft - Control 24.0507567
GSM967854U87-EV human glioblastoma xenograft - Control 33.9302265
GSM967855U87-EV human glioblastoma xenograft - Control 44.3157269
GSM967856U87-EV human glioblastoma xenograft - Control 54.0297967
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.0588966
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.7769962
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.1269168
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.0340967
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.1431968
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.1900868
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.0516167
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.0399667
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.0368567